NCT04667234 is a clinical trial of AMG 510 in Non Small-cell Lung Cancer, sponsored by Amgen.

Who is sponsoring NCT04667234?

NCT04667234 is sponsored by Amgen.

What drugs are being tested in NCT04667234?

Interventions in NCT04667234: AMG 510.

What condition does NCT04667234 study?

NCT04667234 studies Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC.

Is NCT04667234 still recruiting?

NCT04667234 is currently no longer available. Last updated 13 August 2025.

Last reviewed 2025-08-13 · How we verify

NCT04667234

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access of Sotorasib

NO LONGER AVAILABLE Last updated 13 August 2025

What this trial tests

trial testing AMG 510 in Non Small-cell Lung Cancer. No longer available.

Quick facts

Lead sponsor	Amgen
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	55 locations across Taiwan, Saudi Arabia, Israel, Argentina, United States, Brazil

Drugs / interventions tested

AMG 510 — full drug profile →

Conditions studied

Non Small-cell Lung Cancer — all drugs for Non Small-cell Lung Cancer →
Locally Advanced Unresectable NSCLC — all drugs for Locally Advanced Unresectable NSCLC →
Locally Advanced Metastatic NSCLC — all drugs for Locally Advanced Metastatic NSCLC →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 99, any sex, with Non Small-cell Lung Cancer or Locally Advanced Unresectable NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

KRAS mutation: from undruggable to druggable in cancer.
Huang L, Guo Z, Wang F, Fu L. · · 2021 · cited 728× · PMID 34776511 · DOI 10.1038/s41392-021-00780-4
The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
Sotorasib: First Approval.
Blair HA. · · 2021 · cited 161× · PMID 34357500 · DOI 10.1007/s40265-021-01574-2
The path to the clinic: a comprehensive review on direct KRAS<sup>G12C</sup> inhibitors.
Kwan AK, Piazza GA, Keeton AB, Leite CA. · · 2022 · cited 142× · PMID 35045886 · DOI 10.1186/s13046-021-02225-w
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D, Kroemer G, Kang R. · · 2021 · cited 65× · PMID 34607583 · DOI 10.1186/s12943-021-01422-7
Targeting Small GTPases and Their Prenylation in Diabetes Mellitus.
Gendaszewska-Darmach E, Garstka MA, Błażewska KM. · · 2021 · cited 34× · PMID 34236862 · DOI 10.1021/acs.jmedchem.1c00410
RAS degraders: The new frontier for RAS-driven cancers.
Escher TE, Satchell KJF. · · 2023 · cited 32× · PMID 36945775 · DOI 10.1016/j.ymthe.2023.03.017
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y, Yang Y, Zhu G, Zeng H, et al · · 2023 · cited 24× · PMID 37496997 · DOI 10.7150/ijbs.83026

Verify or expand the search:

Other trials of AMG 510

Trials testing the same drug.

NCT05180422 — A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C · Phase 1, PHASE2 · withdrawn
NCT05118854 — A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Res · Phase 2 · recruiting
NCT05599828 — A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants · Phase 1 · completed
NCT04303780 — Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). · Phase 3 · active not recruiting
NCT04380753 — AMG 510 Ethnic Sensitivity Study (CodeBreaK 105). · Phase 1 · completed

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04667234 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 13 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04667234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing